Jupiter Asset Management Ltd. Has $6.90 Million Holdings in Twist Bioscience Corporation $TWST

Jupiter Asset Management Ltd. grew its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 362.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 245,098 shares of the company’s stock after purchasing an additional 192,072 shares during the quarter. Jupiter Asset Management Ltd. owned about 0.41% of Twist Bioscience worth $6,897,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its stake in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Twist Bioscience during the 2nd quarter worth about $97,000. CWM LLC raised its position in shares of Twist Bioscience by 61.4% in the 3rd quarter. CWM LLC now owns 4,331 shares of the company’s stock worth $122,000 after acquiring an additional 1,648 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Twist Bioscience by 8.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock valued at $222,000 after purchasing an additional 469 shares during the period. Finally, AXQ Capital LP bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $226,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Barclays boosted their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Evercore raised their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Finally, Stephens started coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.88.

Twist Bioscience Trading Down 7.4%

TWST opened at $48.59 on Friday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $57.88. The firm has a market capitalization of $2.98 billion, a PE ratio of -37.96 and a beta of 2.24. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The company’s 50-day moving average is $40.59 and its 200 day moving average is $33.15.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.Twist Bioscience’s quarterly revenue was up 16.9% on a year-over-year basis. As a group, research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 7,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the sale, the chief financial officer owned 130,031 shares in the company, valued at $6,501,550. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jan Johannessen sold 2,200 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $47.91, for a total transaction of $105,402.00. Following the transaction, the director owned 17,754 shares in the company, valued at approximately $850,594.14. This trade represents a 11.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,609 shares of company stock valued at $1,665,151 in the last three months. Insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.